Instrument | Purpose | N studies | Population/setting | Countries in which the studies were conducted | Internal consistency (alpha) | Test-retest reliability | Factor structure | Mean score difference with paper version | Convergent validity | Criterion validity (AUC) |
---|---|---|---|---|---|---|---|---|---|---|
GAD | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  GAD-1 | Screening | 1 | G1 | NL |  |  |  |  |  | .78 (1) |
  GAD-2 | Screening | 1 | G1 | NL |  |  |  |  |  | .76 (1) |
  GAD-7 | Screening & symptom severity | 1 | G1 | NL | .86 (1) |  | 1 factor (1) |  | (1) | .77 (1) |
  GAD-7 BSL | Symptom severity | 1 | P6 | UK | .88 (1) |  | 1 factor (1) |  | (1) |  |
  PDI GAD | Diagnosis & screening | 1 | P1 | US |  |  |  |  | (1) | (1) |
Panic disorder and agoraphobia | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  ACQ | Symptom severity | 2 | G1 | AU, SE | .81–.84 (2) |  |  | None, lower (2) |  |  |
  BSQ | Symptom severity | 2 | G1 | AU, SE | .84–.86 (2) |  |  | None, lower (2) |  |  |
  CIDI-Panic subscale | Diagnosis & screening | 1 | G1 | SE |  |  |  |  |  | (1) |
  MI | Symptom severity | 2 | G1 | AU, SE | .94–.97 (2) |  |  | None, higher (2) |  |  |
  PDSS-SR item 4 | Screening | 1 | G1 | NL |  |  |  |  |  | .68 (1) |
  PDSS-SR item 5 | Screening | 1 | G1 | NL |  |  |  |  |  | .61 (1) |
  VS-CMD-agoraphobia | Screening | 1 | G1 | NL |  |  |  |  |  | .73 (1) |
Social phobia | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  LSAS-SR | Symptom severity | 2 | G1, P3 | SE | .93–.94 (2) |  |  | None (1) |  |  |
  SIAS | Symptom severity | 3 | G5, P3 | SE, US | .86–.93 (3) |  | 1 factor (1) | None (2) | (2) |  |
  SPIN | Symptom severity | 1 | G1 | TW | .94 (1) | (1) | 3 factors (1) |  |  | .87 (1) |
  SPS | Symptom severity | 2 | G5, P3 | SE, US | .89–.93 (2) |  | 1 factor (1) | None (2) | (1) |  |
Specific phobia (aviophobia) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  FAS | Screening & symptom severity | 1 | G1 + G5 | US | .94–.99 (1) |  |  |  |  | .99 (1) |
OCD | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  C-FOCI | Screening | 1 | G4 | US | .73 (1) |  |  |  |  |  |
  OBQ-44 | Symptom severity | 1 | G5 | US | .97 (1) |  |  | None (1) | (1) |  |
  OCI | Symptom severity | 1 | G5 | US | .94 (1) |  |  | None (1) | (1) |  |
  PI | Symptom severity | 1 | G1 | US (mainly) |  |  | 4 factors (1) |  |  |  |
PTSD | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  NSES | Diagnosis & symptom severity | 1 | G1, G7 | US |  |  | 4 factors (1) |  |  |  |
  PCL-C | Symptom severity | 1 | G5 | US | .91 (1) |  |  | None (1) |  |  |
  PSS | Screening & symptom severity | 1 | G5 | US | .92–.94 (1) |  | 4 factors (1) |  | (1) |  |
  TSS | Symptom severity | 1 | G5 | US | .95–.96 (1) |  |  | None (1) |  |  |
  PTSD (peripartum) |  |  |  |  |  |  |  |  |  |  |
    PPQ (modified) | Screening & symptom severity | 1 | G2 | US | .90 (1) |  | 3 factors (1) |  | (1) | (1) |